Bioniche Appoints CEO

Michael Berendt has been appointed chief executive officer of Bioniche Life Sciences Inc. Dr. Berendt replaces Graeme McRae, who plans to retire and assume the role of founder and chairman emeritus of the board of directors.
 
Dr. Berendt has held positions of increasing responsibility in the U.S. research departments at Pfizer and Bayer Corp. He also served as managing director of the Life Sciences Sector of AEA Investors, and managing director of Research Corporation Technologies. In 2006, he became the president and chief executive officer of Aegera, which was sold to Pharmascience in 2011.
 
“The board of directors, management team, employees and shareholders acknowledge Graeme’s significant contribution, while welcoming Dr. Berendt to the Bioniche team,” said James Rae, chairman at Bioniche Life Sciences. “Dr. Berendt has an established background in the life sciences sector, most recently serving as president and chief executive officer of Aegera Therapeutics Inc. in Montréal, Québec.”